Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages.
We believe it doesn’t have to be this way.
Assembled a deep clinical evidence library with data collected from more than 1,200 subjects
More than 20 premier cancer institutions around the world participated in our clinical trials
IONIQ's ProLung Test was awarded “Breakthrough Device Designation” by US FDA for its life-enhancing potential
Robust, growing intellectual portfolio of patents and know-how
IONIQ Sciences Announces the Appointment of Aaron B. Dorny to its Board of Directors Salt Lake City, UT, October 7, 2021 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”), is developing a rapid and non-invasive Multi-Cancer Screen for early detection that has the potential to
Salt Lake City, UT, September 23, 2021 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”), is developing a rapid and non-invasive Multi-Cancer Screen for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. Today
IONIQ Sciences has received a new Canadian Patent to add to our robust, growing intellectual portfolio of patents and know-how. We now have 8 company patents and 4 patent applications, with an additional 4 licensed patents. These valuable corporate assets will help ensure that our
